

## 7. Literaturverzeichnis

- ALEXANDER, R.W., DAVIS, J.N., LEFKOWITZ, R.J.: Direct identification and characterization of  $\beta$ -adrenergic receptors in the rat brain. *Nature* 258: 437-440, 1975
- ALMEIDA, S.S., DE OLIVEIRA, L.M., GRAEFF, F.G.: Early life protein malnutrition changes exploration of the elevated plus-maze and reactivity to anxiolytics. *Psychopharmacology* 103: 513-518, 1991
- AL-MERANI, S.A.M.A., BROOKS, D.P., CHAPMAN, B.J., MUNDRY, K.A.: The half-lives of angiotensin II, angiotensin II-amide, angiotensin III, Sar1-Ala8-angiotensin II and renin in the circulatory system of the rat. *J. Physiol.* 278: 471-490, 1978
- ARTAIZ, I., ROMERO, G., ZAZPE, A., MONGE, A., CALDERO, J.M., ROCA, J., LASHERAS, B., DEL RIO, J.: The pharmacology of VA21B7: An atypical 5-HT<sub>3</sub> receptor antagonist with anxiolytic-like properties in animal models. *Psychopharmacology* 117: 137-148, 1995
- BACHMANN, S., PETERS, J., ENGLER, E., GANTEN, D., MULLINS, J.: Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. *Kidney Int.* 41: 24-36, 1992
- BARNES, N.M., COSTALL, B., KELLY, M.E., MURPHY, D.A., NAYLOR, R.J.: Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. *Neuroreport* 2: 351-353, 1991
- BELCHEVA, I., GEORGIEV, V., CHOBANOVA, M., HADJIIVANOVA, C.: Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. *Neuropeptides* 31: 60-64, 1997
- BELLIN, S.I., BHATNAGAR, R.K., JOHNSON, A.K.: Periventricular noradrenergic systems are critical for angiotensin-induced drinking and blood pressure responses. *Brain Res.* 403: 105-112, 1987
- BILKEI-GORZO, A., GYERTYAN, I., LEVAY, G.: MCPP-induced anxiety in the light-dark box in rats: A new method for screening anxiolytic activity. *Psychopharmacology* 136: 291-298, 1998
- BLANCHARD, R.J., TAUKULIS, H.K., RODGERS, R.J., MAGEE, L.K., BLANCHARD, D.C.: Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. *Pharmacol. Biochem. Behav.* 44: 673-681, 1993
- BLUM, B., ZACKS, S.: Analysis of the relationship between drug-induced convulsions and mortality in rats. *J. Pharmacol. Exp. Ther.* 124: 350-356, 1958

BLUMSTEIN, L.K., CRAWLEY, J.N.:  
Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines.  
*Pharmacol. Biochem. Behav.* 18: 37-40, 1983

BORBELY, A.A., HUSTON, J.P., WASER, P.G.:  
Control of sleep states in the rat by short light-dark cycles.  
*Brain Res.* 95: 89-101, 1975

BRADWEJN, J., KOSZYCKI, D., SHIRQUI, C.:  
Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorders. Clinical and behavioral findings.  
*Arch. Gen. Psychiatry* 48: 603-610, 1991

BRASZKO, J.J., WISNIEWSKI, K., KUPRYSZEWSKI, G., WITCZUK, B.:  
Psychotropic effects of angiotensin II and III in rats: Locomotor and exploratory vs cognitive behaviour.  
*Behav. Brain. Res.* 25: 195-203, 1987

BREM, G.:  
Transgenic animals.  
In: *Biotechnology*. Edited by H.J. Rehm, G. Reed, Weinheim, pp. 745-832, 1993

BRITTON, D.R., BRITTON, K.T.:  
A sensitive open field measure of anxiolytic drug activity.  
*Pharmacol. Biochem. Behav.* 15: 557-582, 1981

BROEKKAMP, C.L., BERENDSEN, H.H., JENCK, F., VAN DELFT, A.M.:  
Animal models of anxiety and response to serotonergic drugs.  
*Psychopathology* 22: 2-12, 1989

BRUNNER, H.:  
Zur Pharmakologie der Betablocker.  
In: *Betablocker und Zentralnervensystem*. Edited by P. Kielholz, Hans Huber Verlag, Bern, Stuttgart, Wien, pp. 11-19, 1978

CADOGAN, A.K., KENDALL, D.A., FINK, H., MARSDEN, C.A.:  
Social interaction increases 5-HT release and cAMP efflux in the rat ventral hippocampus in vivo.  
*Behav. Pharmacol.* 5: 299-305, 1994

CALHOUN, J.B.:  
The ecology and sociology of the Norway rat.  
*U.S. Government Printing Office*, Washington, 1962

CAMPBELL, D.J.:  
Tissue renin-angiotensin system: Sites of angiotensin formation.  
*J. Cardiovasc. Pharmacol.* 10: 1-8, 1987

CHAOULOFF, F., CASTANON, N., MORMEDE, P.:  
Paradoxical differences in animal models of anxiety among the Roman rat lines.  
*Neurosci. Lett.* 182: 217-221, 1994

CHARNEY, D.S., WOODS, S.W., GOODMAN, W.K., HENINGER, G.R.: Serotonin function in anxiety. II effects of the serotonin agonist mCPP on panic disorder patients and healthy subjects.  
*Psychopharmacology* 92: 14-21, 1987

CHIU, A.T., HERBLIN, W.F., MC CALL, D.E., ARDECKY, R.J., CARINI, D.J., DUNCIA, J.V., PEASE, L.J., WONG, P.C., WEXLER, R.R., JOHNSON, A.L., TIMMERMANS, P.B.: Identification of angiotensin II receptor subtypes.  
*Biochem. Biophys. Res. Commun.* 165: 196-203, 1989a

CHIU, A.T., MC CALL, D.E., NGUYEN, T.T., CARINI, D.J., DUNCIA, J.V., HERBLIN, W.F., UYEDA, R.T., WONG, P.C., WEXLER, R.R., JOHNSON, A.L., TIMMERMANS, P.B.: Discrimination of angiotensin II receptor subtypes by dithiothreitol.  
*Eur. J. Pharmacol.* 170: 117-118, 1989b

CHOPIN, P., BRILEY, M.: The benzodiazepine agonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.  
*Psychopharmacology* 110: 409-414, 1993

CHOPIN, P., BRILEY, M.: Animal models of anxiety: The effect of compounds that modify 5-HT neurotransmission.  
*Trends Pharmacol. Sci.* 8: 383-388, 1987

CHRISTMAS, A.J., MAXWELL, D.R.: A comparison of the effects of some benzodiazepines and other drugs on aggressive and exploratory behaviour in mice and rats.  
*Neuropharmacology* 9: 17-29, 1970

COLE, B.J., HILLMANN, M., SEIDELMANN, D., KLEWER, M., JONES, G.H.: Effects of benzodiazepine receptor partial inverse agonist in the elevated plus maze test of anxiety in the rat.  
*Psychopharmacology* 121: 118-126, 1995

CONNELL, J., GRAEFF, F., GUIMARAES, F., HELLEWELL, L., HETEM, L.A., DEAKIN, J.F.W.: 5-HT<sub>2</sub> receptors and anxiety.  
*Behav. Pharmacol.* 6: 35, 1995

COOPER, J.S.: Benzodiazepines as appetite-enhancing compounds.  
*Appetite* 1: 1-19, 1980

COOPER, S.J.: Benzodiazepin-opiate antagonist interaction in relation to feeding and drinking behavior.  
*Life Sci.* 32, 1984

COSTALL, B., DOMENEY, A.M., GERRARD, P.A., HOROVITZ, Z.P., KELLY, M.E., NAYLOR, R.J., TOMKINS D.M.: Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset.  
*Pharmacol. Biochem. Behav.* 36: 13-20, 1990

COSTALL, B., DOMENEY, A.M., HUGHES, J., KELLY, M.E., NAYLOR, R.J., WOODRUFF, G.N.: Anxiolytic effects of CCK-B antagonists. *Neuropeptides* 19: 65-73, 1991

COSTALL, B., JONES, B.J., KELLY, M.E., NAYLOR, R.J., TOMKINS, D.M.: Exploration of mice in a black and white box test: Validation as a model of anxiety. *Pharmacol. Biochem. Behav.* 32: 777-785, 1989

COSTALL, B., HENDRIE, C.A., KELLY, M.E., NAYLOR, R.J.: Actions of sulpiride and tiapride in a simple model of anxiety in mice. *Neuropharmacology* 26: 195-200, 1987

CRAWLEY, J.N., DAVIS, L.G.: Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. *Brain Res. Bull.* 8: 609-612, 1982

CRAWLEY, J.N., GOODWIN, F.K.: Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. *Pharmacol. Biochem. Behav.* 13: 167-170, 1980

CRAWLEY, J.N., PAYLOR, R.: A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. *Horm. Behav.* 31: 197-211, 1997

CRITCHLEY, M.A., HANDLEY, S.L.: 5-HT<sub>1A</sub> ligand effects in the x-maze anxiety test. *Br. J. Pharmacol.* 92: 660, 1987a

CRITCHLEY, M.A., HANDLEY, S.L.: Effects in the x-maze anxiety model of agents acting at 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptors. *Psychopharmacology* 93: 502-506, 1987b

CROW, T.J., ARBUTHNOTT, G.W.: Function of catecholamine-containing neurones in mammalian central nervous system. *Nature New Biol.* 238: 245, 1972

DAVIS, M.: Animal models of anxiety based on classical conditioning: The conditioned emotional response and the fear-potentiated startle effect. In *Psychopharmacology of Anxiolytics and Antidepressants*. Edited by S.E. File, Pergamon Press, New York, pp. 187-212, 1991

DAWSON, G.R., TRICKLEBANK, M.D.: Use of the elevated plus maze in the search for novel anxiolytic agents. *Trends Pharmacol. Sci.* 16: 33-37, 1995

DE MONTIGNY, C.: Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. *Gen. Psychiatry* 46: 511-517, 1989

DURCAN, M.J., LISTER, R.G.:  
Does directed exploration influence locomotion activity in a holeboard test?  
*Behav. Neural. Biol.* 51: 121-125, 1989

EPSTEIN, A.N., FITZSIMONS, J.T., ROLLS, B.J.:  
Drinking induced by injection of angiotensin into the brain of rat.  
*J. Physiol.* 210: 457-474, 1970

ESPLIN, D.W., ZABLOCKA-ESPLIN, B.:  
Mechanisms of actions of convulsants.  
In: *Basic mechanisms of the epilepsies*. Edited by Jasper, H.H., Ward, A.A., Pope, A., Little, Brown and Co, Boston, 167-183, 1969

FALTER, U., GOWER, A.J., GOBERT, J.:  
Resistance of baseline activity in the elevated plus-maze to exogenous influences.  
*Behav. Pharmacol.* 3: 123-128, 1992

FILE, S.E., HYDE, J.R.:  
Can social interaction be used to measure anxiety?  
*Br. J. Pharmacol.* 62: 19-24, 1978

FILE, S.E., JOHNSTON, A.L.:  
Lack of effects of 5-HT<sub>3</sub> receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat.  
*Psychopharmacology* 99: 248-251, 1989

FILE, S.E., VELLUCCI, S.V.:  
Behavioural and biochemical measures of stress in hooded rats from different sources.  
*Physiol. Behav.* 22: 31-35, 1979

FILE, S.E., WARDILL, A.G.:  
Validity of headdipping as a measure of exploration in a modified hole-board.  
*Psychopharmacology* 44: 53-59, 1975b

FILE, S.E., WARDILL, A.G.:  
The reliability of the hole-board apparatus.  
*Psychopharmacologia* 44: 47-51, 1975a

FILE, S.E., ZANGROSSI, H., ANDREWS, N.:  
Social interaction and elevated plus-maze tests: Changes in release and uptake of 5-HT and GABA.  
*Neuropharmacology* 32: 217-221, 1993

FILE, S.E.:  
Behavioral effects of pentylenetetrazole reversed by chlordiazepoxide and enhanced by RO 15-1788.  
*Naunyn-Schmiedebergs Arch. Pharmacol.* 326: 129-131, 1984

FILE, S.E.:  
What can be learned from the effects of benzodiazepines on exploratory behavior?  
*Neurosci. Biobehav. Rev.* 9: 45-54, 1985b

FILE, S.E.:  
Models of anxiety.  
*Br. J. Clin. Pract. Symp. Suppl.* 38: 15-20, 1985a

FILE, S.E.:

The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs.

*Neurosci. Methods* 2: 219-238, 1980

FILE, S.E.:

Variability in behavioral responses to benzodiazepines in the rat.

*Pharmac. Biochem. Behav.* 18: 303-306, 1983

FILE, S.E.:

Long-lasting anticonvulsant effects of diazepam are strain dependent.

*Soc. Neurosci. Abstract.* 9: , 1983

FILE, S.E.:

Behavioural detection of anxiolytic action.

In: *Experimental Approaches to Anxiety and Depression*. Edited by J.M. Elliott, D.J. Heal, C.A. Marsden, John Wiley & Sons Ltd, New York, pp.25-44, 1992

FILE, S.E.:

Animal models of different anxiety states.

*Adv. Biochem. Psychopharmacol.* 48: 93-113, 1995

FILE, S.E.:

The contribution of behavioural studies to the neuropharmacology of anxiety.

*Neuropharmacology* 26: 877-886, 1987

FILE, S.E.:

Can social interaction be used to measure anxiety?

*Brain J. Pharmacology* 62: 19-24, 1978

FILE, S.E.:

Strain differences in mice in the development of tolerance to the anti-pentylenetetrazole effects of diazepam.

*Neurosci. Lett.* 42: 95-98, 1983

FINK, H., REX, A., VOITS, M., VOIGT, J.-P.:

Major biological action of CCK-a critical evalution of research findings.

*Exp. Brain Res.* 123: 77-83, 1998

FREYBERGER, H.J., STIEGLITZ, R.-D.:

Neurotische, somatoforme und Belastungsstörungen.

In: *Kompendium der Psychiatrie und Psychotherapie*. pp. 169-172, 1991

FRITH, C.D., RICHARDSON, J.T.E., SAMUEL, M., CROW, T.J., McKENNA, P.J.:

The effects of intravenous diazepam and hyoscine upon human memory.

*Q. J. Exp. Psychol. A.* 36: 133-144, 1984

GANONG, W.F.:

The brain renin-angiotensin system.

*Annu. Rev. Physiol.* 46: 17-31, 1984

GAO, B., CUTLER, M.G.:

Effects of acute and subchronic administration of propranolol on the social behaviour of mice:  
An ethopharmacological study.

*Neuropharmacology* 31: 749-756, 1992

BRUNNER, E., LANGER, F.:

Versuchsanlagen für mehrere Gruppen.

In: *Nichtparametrische Analyse longitudinaler Daten*. Edited by E.Brunner, E.Langer, B.Oldenbourg Verlag, München, Wien, pp. 97-99, 1999

GELBAND, C.H., SUMMERS, C., LU, D., RAIZADA, M.K.:

Angiotensin receptors and norepinephrine neuromodulation: Implications of functional coupling.

*Regul. Pept.* 73: 141-147, 1998

GELLER, I., SEIFTER, J.:

The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat.

*Psychopharmacologia* 1: 482-492, 1960

GERLAI, R.:

Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype?

*Trends Neurosci.* 19: 177-181, 1996

GLOWA, J.R., HANSEN, C.T.:

Differences in response to an acoustic startle stimulus among forty-six rat strains.

*Behav. Genet.* 24: 79-84, 1994

GRADY, E.F., SECHI, L.A., GRIFFIN, C.A., SCHAMBELAN, M., KALINYAK, J.E.:

Expression of AT2 receptors in the developing rat fetus.

*J. Clin. Invest.* 88: 921-933, 1991

GRAEFF, F.G., GUIMARAES, F.S., DE ANDRADE, T.G.C.S., DEAKIN, J.F.W.:

Role of 5-HT in stress, anxiety and depression.

*Pharmacol. Biochem. Behav.* 54: 129-141, 1996

GRAY, J.A., DAVIS, N., FELDON, J., NICHOLAS, J., RAWLINS,P., OWEN, S.R.:

Animal models of anxiety.

*Prog. Neuro-Psychopharmacol.* 5: 143-157, 1981

GREEN, S., HODGES, H.:

Animal models of anxiety.

In: *Behavioural Models in Psychopharmacology*. Edited by P. Willner, University Press, Cambridge, pp. 21-49, 1991

GRIEBEL, G., BELZUNG, C., MISSLIN, R., VOGEL, E.:

The free-exploratory paradigm: An effective method for measuring neophobic behaviour in mice and testing potential neophobia-reducing drugs.

*Behav. Pharmacol.* 4: 637-644, 1993

GRIEBEL, G.:

5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research.

*Pharmacol. Ther.* 65: 319-395, 1995

GRONEIM, M.M., HINRICHES, J.V., MEHWALDT, S.P.:

Dose-response analysis of the behavioural effects of diazepam. (I) Learning and memory.

*Psychopharmacology* 82: 291-295, 1984

GUIMARAES, F.S., CHIARETTI, T.M., GRAEFF, F.G., ZUARDI, A.W.:  
Antianxiety effect of cannabidiol in the elevated plus-maze.  
*Psychopharmacology* 100: 558-559, 1990

GUITART, X., KOGAN, J.H., BERHOW, M., TERWILLINGER, R.Z.,  
AGHAJANIAN, G.K., NESTLER, E.J.:  
Lewis and Fischer rat strains display differences in biochemical,  
electrophysiological and behavioral parameters: Studies in the nucleus  
accumbens and locus coeruleus of drug naive and morphine-treated animals.  
*Brain Res.* 611: 7-17, 1993

HANDLEY, S.L., MITHANI, S.:  
Effects of alpha-adrenoceptor agonist in a maze-exploration model of „fear“-motivated  
behavior.  
*Nauny Schmiedebergs Arch. Pharmacol.* 327: 1-5, 1984

HEALY, D.P., PRINTZ, M.P.:  
Autoradiographic localization of angiotensin II binding sites in the brain, pituitary, kidney and  
adrenal gland of the rat.  
*J. Hypertens.* 2: 57-61, 1984

HEEMSKERK, F.M.J., SAAVEDRA, J.M.:  
Quantitative autoradiography of angiotensin II AT<sub>2</sub> receptors with [<sup>125</sup>I]CGP 42112.  
*Brain Res.* 677: 29-38, 1995

HENDRIE, C.A., WEISS, S.M., EILAM, D.:  
Exploration and predation models of anxiety: Evidence from laboratory and wild species.  
*Pharmacol. Biochem. Behav.* 54/1: 13-20, 1996

HERMANN, K., GANTEN, D., BAYER, C., UNGER, T., LANG, R.E., RASCHER, W.:  
Definite evidence for the presence of [Ile<sup>5</sup>] - angiotensin I and [Ile<sup>5</sup>] -angiotensin II in the brain  
of rats.  
*Exp. Brain Res.* 4: 192-207, 1982

HLINAK, Z., ROZMAROVA, E.:  
The locomotor-exploratory behaviour of laboratory male rats tested under the „red“ and  
„white“ light condition.  
*Activ. Nerv. Sup.* 3: 28, 1986

HOWARD, J.L., POLLARD, G.T.:  
Effects of drugs on punished behavior: Preclinical test for anxiolytics.  
In: *Psychopharmacology of Anxiolytics and Antidepressants*. Edited by S.E. File, Pergamon  
Press, New York, pp.131-153, 1986

HUGHES, R.N.:  
Intrinsic exploration in animals - motives and measurement.  
*Behav. Process* 41: 213-226, 1997

HUGHES, R.N.:  
Behaviour of male and female rats with a free choice of two environments differing in novelty.  
*Animal Behav.* 16: 92-96, 1968

JOHNSON, D.N.:  
Effects of diazepam on food consumption in rats.  
*Psychopharmacology* 56: 111-112, 1978

KAISER, F.C., PALMER, G.C., WALLACE, A.V., CARR, R.D., FRASER-RAE, L., HALLAM, C.:  
Antianxiety properties of the angiotensin II antagonist, DuP 753, in the rat using the elevated plus-maze.  
*NeuroReport* 3: 911-924, 1992

KASPER, S., RUHRMANN, S.:  
Angst und Panikstörungen.  
*Arzneimitteltherapie* 4: 118-127, 1993

KENNETT, G.A.:  
5-HT<sub>1C</sub> receptors and their therapeutic relevance.  
*Curr. Opin. Invest. Drugs* 2: 317-362, 1993

KIELHOLZ, P.:  
Eröffnungsansprache.  
In: *Betablocker und Zentralnervensystem*. Edited by P.Kielholz, Hans Huber Verlag, Bern, Stuttgart, Wien, pp. 9-10, 1978

KISCHKA, U., WALLESCH, C.-W., WOLF, G.:  
Verhaltensforschung.  
In: *Methoden der Hirnforschung. Eine Einführung*. Edited by U. Kischka, C.-W. Wallesch, G. Wolf, Spektrum Akad. Verlag, pp. 191-209, 1997

KOELLA, W.B.:  
Die zentralen Wirkungen der Betablocker- anatomische, physiologische und pharmakologische Befunde.  
In: *Betablocker und Zentralnervensystem*. Edited by P.Kielholz, Hans Huber Verlag, Bern, Stuttgart, Wien, pp. 20-34, 1978

KOSTEN, T.A., MISERENDINO, M.J., CHI, S., NESTLER, E.J.:  
Fischer and Lewis rat strains show differential cocaine effects in conditioned place preference and behavioral sensitization but not in locomotor activity or conditioned taste aversion.  
*J. Pharmacol. Exp. Ther.* 269: 137-144, 1994

KOSTOWSKI, W., DYR, W., KRZASCIK, P., JARBE, T., ARCHER, T.:  
5-Hydroxytryptamine 1 A receptor agonist in animal models of depression and anxiety.  
*Pharmacol. Toxicol.* 71: 24-30, 1992

KRSIAK, M., SULCOVA, A., DONAT, P., TOMASIKOVA, Z., DLOHOZKOVA, N., KOSAR, E., MASEK, K.:  
Can social and agonistic interactions be used to detect anxiolytic activity of drugs?  
In: *Ethopharmacological Aggression Research*. Edited by K.A. Miczek, M.R. Kruz and B. Olivier, Alan Liss, New York, pp. 93-114, 1984

KULAKOWSKA, A., KARWOWSKA, W., WISNIEWSKI, K., BRASZKO, J.J.:  
Losartan influences behavioural effects of angiotensin II in rats.  
*Pharmacol. Res.* 34: 109-115. 1996

LADER, M.:  
Clinical pharmacology of anxiolytic drugs: past, present and future.  
*Adv. Biochem. Psychopharmacol.* 48: 135-152

LAL, H., EMMETT-OGLESBY, M.W.:  
Behavioral analogues of anxiety.  
*Neuropharmacology* 22: 1423-1441, 1983

LARSSON, K.:  
Conditioning and sexual behavior in the male albino rat.  
*Almquist & Wiksell*, Stockholm, 1956

LEMAIRE, M., PIOT, O., ROQUES, B.P., BÖHME, G.A., BLANCHARD, J.-C.:  
Evidence for an endogenous cholecystokinergic balance in social memory.  
*NeuroReport* 3: 929-932, 1992

LIND, R.W., JOHNSON, A.K.:  
Central and peripheral mechanisms mediating angiotensin-induced thirst.  
In: *The Renin Angiotensin System in the Brain*. Edited by D. Ganter, M. Printz, M.I. Phillips  
and B.A. Schöckens, Springer, Berlin, pp. 353-364, 1982

LISTER, R.G.:  
The effects of ethanol on exploration in DBA/2 and C57BL/6 mice.  
*Alcohol* 4: 17-19, 1987a

LISTER, R.G.:  
Ethologically-based animal models of anxiety disorders.  
*Pharmac. Ther.* 46: 321-340, 1990

LISTER, R.G.:  
The use of a plus-maze to measure anxiety in the mouse.  
*Psychopharmacology* 92: 180-185, 1987b

LU, X.-Y., GROVE, W.Z., SPETH, R.C.:  
Pharmacological characterization of angiotensin II AT<sub>2</sub> receptor subtype heterogeneity in the  
rat adrenal cortex and medulla.  
*Endocrine* 3: 255-261, 1995

MARDER, A.R.:  
Psychotropic drugs and behavioral therapy.  
*Vet. Clinics of North America/Small Anim. Pract.* 21: 329-342, 1991

MARSDEN, C.A., BICKERDIKE, M., CADOGAN, A., WRIGTH, I., REX, A., FINK, H.:  
Serotonergic mechanisms and animal models of anxiety.  
In: *Anxiety: Neurobiology, Clinic and Therapeutic Perspectives Colloque Inserm*. Edited by  
M. Hamon, H. Ollat, M.-H. Thibbot, pp. 75-82, 1993

MATSUO, M., KATAOKA, Y., MATAKI, S., KATO, Y., OI, K.:  
Conflict situation increases serotonin release in rat dorsal hippocampus: In vivo study with  
micro-dialysis and Vogel test.  
*Neurosci. Lett.* 215: 197-200, 1996

MERTENS, P.A., DODMANN, N.H.:  
Pharmacologic treatment of fear and anxiety in animals.  
In: *Psychopharmacology of Animal Behavior Disorders*. Edited by N.H. Dodmann, L. Shuster,  
Blackwell Science, Inc., Malden, pp. 122-140, 1998

MILLAN, M.A., JACOBOWITZ, D.M., AGUILERA, G., CATT, K.J.:  
Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain  
during development.  
*Proc. Natl. Acad. Sci. USA* 88: 11440-11444, 1991

MISSLIN, R., ROPARTZ, P.:  
Effects of methamphetamine on novelty-seeking behaviour by mice.  
*Psychopharmacology* 75: 39-43, 1981

MONTGOMERY, K.C.:  
The relationship between fear induced by novel stimulation and exploratory behavior.  
*J. Comp. Physiol. Psychol.* 48: 254-260, 1955

MONTKOWSKI, A., HOLSBOER, F.:  
Transgene Tiermodelle in der psychiatrischen Forschung.  
*Neuroforum* 1: 25-32, 1996

MORGNER, J.:  
Die Pharmakotherapie der Angsterkrankungen.  
*Psycho* 22: 116-126, 1996

MORIGUCHI, A., TALLANT, E.A., MATSUMURA, K., REILLY, T.M., WALTON, H., GANTEN, D., FERRARIO, C.M.:  
Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic  
hypertensive rats.  
*Hypertension* 25: 1260-1265, 1995

MOTTA, V., MAISONNETTE, S., MORATO, S., CASTRECHINI, P.,  
BRANDAO, M.L.:  
Effects of blockade of 5-HT<sub>2</sub> receptors and activation of 5-HT<sub>1</sub> receptors on the exploratory  
activity of rats in the elevated plus-maze.  
*Psychopharmacology* 107: 135-139, 1992

MULLINS, J.J., PETERS, J., GANTEN, D.:  
Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene.  
*Nature* 344: 541-544, 1990

NUTT, D.J.:  
Anxiety and its therapy: Today and tomorrow.  
In: *New Concepts in Anxiety*. Edited by M. Briley and S.E. File, Macmillian,  
London, pp. 1-12, 1991

OKUYAMA, S., SAKAGAWA, T., CHAKI, S., IMAGAWA, Y., ICHIKI, T., INAGAMI, T.:  
Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor.  
*Brain Res.* 821: 150-159, 1999

OLIVERIO, A., ELEFTHERIOU, B.E., BAILEY, D.W.:  
Exploratory activity: Genetic analysis of its modification by scopolamine and amphetamine.  
*Physiol. Behav.* 10: 893-899, 1973

PEACH, M.J.:  
Renin-angiotensin system: Biochemistry and mechanism of action.  
*Physiol. Rev.* 57: 313-370, 1977

- PELLOW, S., JOHNSTON, A.L., FILE, S.E.: Selective agonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in rats. *J. Pharm. Pharmacol.* 39: 917-928, 1987
- PELLOW, S., CHOPIN, P., FILE, S.E., BRILEY, M.: Validation of open : closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J. Neuroscience Methods* 14: 149-167, 1985 **54**
- PELLOW, S., FILE, S.E.: Anxiolytic and anxiogenic drug effects in exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. *Pharmacol. Biochem. Behav.* 24: 525-529, 1986
- PERKINS, J.P., MOORE, M.M.: Characterization of the adrenergic receptors mediating a rise in cyclic 3',5'-adenosin monophosphate in rat cerebral cortex. *J. Pharmacol. exp. Ther.* 185: 371, 1973
- PHILLIPS, M.I.: Functions of angiotensin in the central nervous system. *Ann. Rev. Physiol.* 49: 413-435, 1987
- POSCHEL, B.P.H.: A simple and specific screen for benzodiazepine-like drugs. *Psychopharmacologia* 19: 193-198, 1971
- PRINTZ, M.P., GANTEN, D., UNGER, T., PHILLIPS, M.I.: The brain renin-angiotensin system. In: *The Renin-Angiotensin System in the Brain*. Edited by D. Ganen, M.I. Phillips, and B.A. Schölkens, Springer, Berlin, pp. 2-52, 1982
- PRINTZ, M.P.: Regulation of the brain angiotensin system: A thesis of multicellular involvement. *Clin. Exp. Hypertens.* A10: 17-35, 1988
- PUCELL, A.G., HODGES, J.C., SEN, I. BUMPUS, F.M., HUSAIN, A.: Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. *Endocrinology* 128: 1947-1959, 1991
- REX, A., BARTH, T., VOIGT, J.P., DOMENEY, A.M., FINK, H.: Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. *Neurosci. Lett.* 172: 139-142, 1994
- REX, A., SONDERN, U., VOIGT, J.P., FRANCK, S., FINK, H.: Stain differences in fear-motivated behavior of rats. *Pharmacol. Biochem. Behav.* 54: 107-111, 1996a
- REX, A., STEPHENS, D.N., FINK, H.: „Anxiolytic“ action of diazepam and abecarnil in a modified open-field test. *Pharmacol. Biochem. Behav.* 53: 1005-1011, 1996b

REX, A., VOIGT, J.P., FINK, H.:  
Behavioral and neurochemical differences between Fischer 344 and Harlan-Wistar rats raised identically.  
*Behav. Genet.* 29: 187-192, 1999

REX, A., VOIGT, J.P., VOITS, M., FINK, H.:  
Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs.  
*Pharmacol. Biochem. Behav.* 59: 677-683, 1998

RODGERS, R.J., CAO, B.-J., DALVI, A., HOLMES, A.:  
Animal models of anxiety: An ethological perspective.  
*Brazilian Journal of Medical and Biological Research* 30: 289-304, 1997

RODGERS, R.J., COLE, J.C.:  
The elevated plus maze: Pharmacology, methodology and ethology.  
In: *Ethology and Psychopharmacology*. Edited by S.J. Cooper and C.A. Hendrie, John Wiley & Sons Ltd, London pp. 9-44, 1995

RODIN, E.A., CALHOUN, H.D.:  
Metrazol in a „normal“ volunteer population.  
*J. Nerv. Ment. Dis.* 150: 438-450, 1970

RODIN, E.A.:  
Metrazol tolerance in a „normal“ and volunteer population.  
*Electroenceph. Clin. Neurophysiol.* 10: 433-446, 1958

SANDER, M., BADER, M., DJAVIDANI, B., MASER-GLUTH, C., VECSEI, P., MULLINS, J., GANTEN, D., PETERS, J.:  
The role of the adrenal gland in hypertensive transgenic rat TGR(mRen2)27.  
*Endocrinology* 131: 807-814, 1992

SEANAYAKE, P.D., MORIGUCHI, A., KUMAGAI, H., GANTEN, D., FERRARIO, C.M., BROSNIHAN, K.B.:  
Increased expression of angiotensin peptides in the brain of transgenic hypertensive rat.  
*Peptides* 15: 919-926, 1994

SETEM, J., PINHEIRO, A.P., MOTTA, V.A., MORATO, S., CRUZ, A.P.M.:  
Ethopharmacological analysis of 5-HT ligands on the rat elevated plus maze.  
*Pharmacol. Biochem. Behav.* 62: 515-521, 1999

SHANKS, N., GRIFFITHS, J., AMISMAN, H.:  
Norepinephrine and serotonin alterations following chronic stressor exposure: Mouse strain differences.  
*Pharmacol. Biochem. Behav.* 65: 57-65, 1994

SHEPHERD, J., BILL, D.J., DOURISH, C.T., GREWAL, S.S., McLENNACHAN, A., STANHOPE, K.J.:  
Effects of the selective angiotensin II receptor antagonist losartan and PD123177 in animal models of anxiety and memory.  
*Psychopharmacology* 126: 206-218, 1996

SINGH, L., LEWIS, A.S., FIELD, M., HUGHES J., WOODRUFF, G.N.:  
Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.  
*Proc. Nat. Acad. Sci. USA* 88: 1130-1133, 1991

SÖDERPALM, B.:

The SHR exhibits less „anxiety“ but increased sensitivity to the anticonflict effect of clonidine compared to normotensive controls.

*Pharmacol. Toxicol.* 65: 381-386, 1989

STEFANICK, M.L.:

The circadian patterns of spontaneous seminal emission, sexual activity and penile reflexes in the rat.

*Physiol. Behav.* 31: 737-743, 1983

STEIN, D.J.:

Introduction: steps toward a comparative clinical psychpharmacology.

In: *Psychopharmacology of Animal Behavior Disorders*. Edited by N.H. Dodmann, L. Shuster, Blackwell Science, Inc., Malden, pp. 1-14, 1998

STEPHENS, D.N., ANDREWS, J.S.:

Screening for anxiolytic drugs.

In: *Behavioural models in psychopharmacology: Theoretical, industrial and clinical perspectives*. Edited by P. Willner, Cambridge University Press pp. 50-75, 1991

SUMNERS, C.:

Norepinephrine increases angiotensin II binding in rat brain synaptosomes.

*Brain Res. Bull.* 28: 411-415, 1992

TAUKULIS, H.K., GOGGIN, C.E.:

Diazepam-stress interactions in the rat: Effects on autoanalgesie and a plus-maze model of anxiety.

*Behav. Neural. Biol.* 53: 205-216, 1990

TIMMERMANS, P.B., WONG, P.C., CHIU, A.T., HERBLIN, W.F., BENFIELD, P., CARINI, D.J., LEE, R.J., WEXLER, R.R., SAYE, J.A., SMITH, R.D.:

Angiotensin II receptors and angiotensin II receptor antagonists.

*Pharmacol. Rev.* 45: 205-251, 1993

TREIT, D., MENARD, J., ROYAN, C.:

Anxiogenic stimuli in the elevated plus-maze.

*Pharmacol. Biochem. Behav.* 44: 463-469, 1993

TREIT, D.:

Animal models for the study of anti-anxiety agents.

*Neurosci. Biobehav. Rev.* 9: 203-222, 1985

TRULLAS, R., SKOLNICK, P.:

Differences in fear motivated behaviors among inbred mouse strains.

*Psychopharmacology* 111: 323-331, 1993

TSUTSUMI, K., SAAVEDRA, J.M.:

Characterization and development of angiotensin II receptor subtypes (AT 1 and AT 2) in rat brain.

*Am. J. Physiol.* 261: R209-R216, 1991

VOGEL, J.R., BEER, B., CLODY, D.E.:

A simple and reliable conflict procedure for testing anti-anxiety agents.

*Psychopharmacologia* 21: 1-7, 1971

VOIGT, J.-P., REX, A., BADER, M., FINK, H.:  
From genotype to phenotype - behavior of the transgenic rat TGR(mRen2)27 as an example.  
*Rev. Neurosci.* 11: 37-45, 2000

VOIGT, J.-P., REX, A., SOHR, R., FINK, H.:  
Hippocampal 5-HT and NE release in the transgenic rat TGR(mRen2)27 related to behavior  
on the elevated plus maze.  
*Eur. Neuropsychopharmacol.* 4: 279-285, 1999

WALSH, R.N., CUMMINS, R.A.:  
The open-field test: A critical review.  
*Psychol. Bull.* 83: 482-504, 1976

WEISS, S.M., LIGHTOWLER, S., STANHOPE, K.J., KENNEDY, G.A.,  
DOURISH, C.:  
Measurement of anxiety in transgenic mice.  
*Rev. Neurosci.* 11: 59-74, 2000

WHITEBREAD, S., MELE, M., KAMBER, B., DE GASPARO, M.:  
Preliminary biochemical characterization of two angiotensin II receptor subtypes.  
*Biochem. Biophys. Res. Comm.* 163: 284-291, 1989

WHITTON, P., CURZON, G.:  
Anxiolytic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus.  
*Psychopharmacology* 100: 138-140, 1990

WILSON, W., VOIGT, P., BADER, M., MARSDEN, C.A., FINK, H.:  
Behaviour of the transgenic (mRen2)27 rat.  
*Brain Res.* 729: 1-9, 1996

WISNIEWSKI, K., BRASZKO, J.J.:  
Some aspects of the modulatory action of peptides in CNS.  
*Beitr. Wirkstoffforsch.* 24: 113-123, 1985

WISNIEWSKI, K., BRASZKO, J.J.:  
The significance of central monoamine systems in the angiotensin II (A II) improvement of  
learning.  
*Clin. Exper. Hypertens.-Theory and Practice* A6: 2127-2131, 1984

WRIGHT, I.K., HEATON, M., UPTON, N., MARSDEN, C.A.:  
Comparison of acute and chronic treatment of various serotonergic agents with those of  
diazepam and idazoxan in the rat elevated x-maze.  
*Psychopharmacology* 107: 405-414, 1992a

WRIGHT, I.K., UPTON, N., MARSDEN, C.A.:  
Effect of potential anxiolytics on extracellular 5-HT in the ventral hippocampus observed of  
rats on the elevated x-maze in vivo microdialysis.  
In: *Monitoring molecules in neuroscience*. Edited by H. Rollema, B.H.C. Westerink and W.J.  
Drijfhout, University centre for Pharmacy, Groningen, pp. 208-211, 1991

WRIGHT, I.K., UPTON, N., MARSDEN, C.A.:  
Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral  
hippocampus of rats during behaviour on the elevated x-maze.  
*Psychopharmacology* 109: 338-346, 1992b

WRIGHT, J.W., HARDING, J.W.:  
Brain angiotensin receptor subtypes in the control of physiological and behavioral responses.  
*Neurosci. Behav. Rev.* 18: 21-53, 1994

WRIGHT, J.W., HARDING, J.W.:  
Regulatory role of brain angiotensins in the control of physiological and behavioral  
responses.  
*Brain Res. Rev.* 17: 227-262, 1992

YONKOV, D.I., GEORGIEV, V.P., OPITZ, M.J.:  
Participation of angiotensin II in learning and memory. II. Interaction of angiotensin II with  
dopaminergic drugs.  
*Meth. Find. Exp. Clin. Pharmacol.* 8: 203-206, 1987